SCHEMBL6559348

SCHEMBL6559348

CCCCCCCC[CH]Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.49
DNM1 Q05193 2/20 0.46
EPHX2 P34913 3/20 0.45
FAAH O00519 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PKM P14618 1/20 0.44
HTT P42858 2/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005495 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL27772350 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL6380984 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL7458957 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL10494813 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL442769 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL2549406 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL9386106 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL10494779 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1
SCHEMBL28177024 1.00 KCNH2 (0.49) KCNH2DNM1EPHX2FAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156780-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AXIAL THERAPEUTICS, INC. (US) 2024-05-16 US disclosed
US-11951094-B2 TLR2 modulator compounds, pharmaceutical compositions and uses thereof AXIAL THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
EP-4171547-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Axial Therapeutics, Inc. (US) 2023-05-03 EP disclosed
US-20230051773-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AXIAL THERAPEUTICS, INC. (US) 2023-02-16 US disclosed
WO-2021242923-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AXIAL THERAPEUTICS, INC. (US) 2021-12-02 WO disclosed
CN-110183366-A A method of carbonyl thioesters is inserted by alkene and is combined to sulfur ester 中国科学院成都生物研究所 2019-08-30 CN disclosed
CN-102676280-B Oil composition for automobile hydraulic shock absorber CHINA NAT PETROLEUM CORP 2015-05-27 CN disclosed
CN-101467276-A Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof MAX PLANCK GESELLSCHAFT (DE) 2009-06-24 CN disclosed
EP-0913459-B1 Surfactants XEROX CORP (US) 2004-03-10 EP disclosed
US-6527981-B1 Azole/amine oxide preservatives LONZA INC. 2003-03-04 US disclosed
US-5944650-A PHOSPHOROUS MODIFIED POLYOXYETHYLENE GLYCOL XEROX CORPORATION (US) 1999-08-31 US disclosed
EP-0913459-A1 Surfactants Xerox Corporation (US) 1999-05-06 EP disclosed
EP-0563281-B1 METHOD FOR PROCESSING ELECTRICALLY CONDUCTIVE POLYANILINES IN LEWIS-BASE SOLVENTS MONSANTO CO (US) 1998-08-05 EP disclosed
EP-0563281-A1 METHOD FOR PROCESSING ELECTRICALLY CONDUCTIVE POLYANILINES IN LEWIS-BASE SOLVENTS AlliedSignal Inc. (US) 1993-10-06 EP disclosed
WO-1992011645-A1 METHOD FOR PROCESSING ELECTRICALLY CONDUCTIVE POLYANILINES IN LEWIS-BASE SOLVENTS ALLIED-SIGNAL INC. (US) 1992-07-09 WO disclosed
US-3988378-A ANTISTATIC AGENTS, STABILIZERS CIBA-GEIGY CORPORATION (US) 1976-10-26 US disclosed
US-3936422-A Anti-static modified thermoplastics CIBA-GEIGY CORPORATION (US) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230051773-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF TLR2, TLR3, TLR4 KCNH2 4714/4885DNM1 4144/4885EPHX2 3924/4885
US-20240156780-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF TLR2, TLR3, TLR4 KCNH2 4714/4885DNM1 4144/4885EPHX2 3924/4885
US-11951094-B2 TLR2 modulator compounds, pharmaceutical compositions and uses thereof TLR2, TLR3, TLR4 KCNH2 4714/4885DNM1 4144/4885EPHX2 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.